Non-Hematological Cancer Market to Post 9.86% CAGR to 2021, States GBI Research in In-demand Report Available at MarketPublishers.com23 May 2016 • by Natalie Aster
LONDON – Non-hematological types of cancer comprise 94% of the global cancer prevalence. The dominant indications such as breast, lung, colorectal and prostate cancer represent close to 51% of the worldwide cancer prevalence.
As populations are anticipated to increase, with ageing and rising obesity incidence rates, the prevalence rate of cancer as a genetic disease is only projected to surge, hence acting as a key force propelling the revenue growth.
There has been a move towards elaborating targeted, less-toxic therapies which can be administered to a larger number of cancer patients, commonly elderly and with co-morbidities. This can lead to the increase in the overall survival of this patient group and the cycles of therapy they may receive.
The non-hematological cancer market is forecast to increase in value registering 9.86% CAGR, with its revenues reaching USD 141 billion in 2021.
All in all, there are 6,484 oncology drug products in development, which make it the dominant therapy field pipeline.
18 of the top 20 pharmacos are set to market non-hematological oncology drugs over the coming years.
In-demand research report “Global Non-Hematological Cancers Market to 2021 - Strong growth driven by increased uptake of low toxicity targeted treatments and versatile biologics” elaborated by GBI Research offers an up-close look at the market on a global level.
The study sheds light on the actual clinical and commercial landscape pertaining to non-hematological cancer types. It examines the structure of the market across each of the indications in question, with respect to dominant molecule types and targets, limelighting the main commercial assets and top players. The report assesses the pipeline, categorising it by stage of development, molecule type and target, including a granular breakdown across key indications. It keeps track of the growth in patient epidemiology and market revenues globally and across the dominant industry participants and key product types. The report evaluates the market as regard to the split between premium and generic products and gives an assessment of the role of these products in treating the cancer types reviewed. Furthermore, an overview of the commercial opportunities in the deals landscape is given, with a focus on prevalent trends in co-development and licensing deals.
More studies by our market research partner are available at GBI Research page.